We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Aligos Therapeutics Inc
6 own
11 watching
Current Price
$29.94
$-4.4
(-12.81%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
43.06M
52-Week High
46.80000
52-Week Low
6.76000
Average Volume
0.63M
Dividend Yield
--
P/E Ratio
--
Market Capitalization43.06M52-Week High46.8000052-Week Low6.76000Average Volume0.63MDividend Yield--P/E Ratio--What does the Aligos Therapeutics Inc do?
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.
Read More
How much money does Aligos Therapeutics Inc make?
News & Events about Aligos Therapeutics Inc.
Benzinga
1 year ago
read more...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company is delivering ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company will deliver ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, ...
Globe Newswire
2years ago
Final cohort of Phase 1 study projected to be complete in H1 2023 Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT SOUTH SAN FRANCISCO, ...
Frequently Asked Questions
Frequently Asked Questions
What is Aligos Therapeutics Inc share price today?
Can Indians buy Aligos Therapeutics Inc shares?
How can I buy Aligos Therapeutics Inc shares from India?
Can Fractional shares of Aligos Therapeutics Inc be purchased?
What are the documents required to start investing in Aligos Therapeutics Inc stocks?
What is today’s traded volume of Aligos Therapeutics Inc?
What is today’s market capitalisation of Aligos Therapeutics Inc?
What is the 52-Week High and Low Range of Aligos Therapeutics Inc?
What percentage is Aligos Therapeutics Inc down from its 52-Week High?
What percentage is Aligos Therapeutics Inc up from its 52-Week Low?
Current Price
$29.94
$-4.4
(-12.81%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.